Glenmark Pharma Share Price Rises Over 3%; Receives US FDA Approval for Nasal Spray

Glenmark Pharmaceuticals has received the U.S. FDA's approval for Fluticasone Propionate Nasal Spray USP, dosed at 0.05 mg or 50 mcg per spray.  

According to its August 20, 2026, exchange filing, the product will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA. 

Linked to Flonase Reference Product 

Glenmark noted that its nasal spray is bioequivalent and therapeutically equivalent to Flonase Nasal Spray, 0.05 mg per spray, from Haleon US Holdings LLC. 

Flonase is the reference listed drug for the approval and is covered under NDA 020121. Glenmark's product can only be marketed for the indications listed on its approved label. 

Market Sales at $295.2 Million 

Glenmark cited IQVIA data showing that Flonase Nasal Spray and its available therapeutic equivalents generated approximately $295.2 million in sales during the year ended June 2026.  

The figure takes into account sales through both retail and non-retail channels. 

Respiratory Portfolio in the U.S. 

Globally, Glenmark runs 11 manufacturing facilities across four continents and six R&D centres. It sells branded, generic and consumer health products in more than 80 countries, including respiratory, dermatology and oncology treatments. 

The product will be part of Glenmark’s respiratory portfolio in the U.S. According to Marc Kikuchi, President and Business Head for North America, the approval comes as the company plans to expand in the category. 

Read More: Reliance Industries Proposes ₹2.73 Lakh Crore Underground Coal Gasification Project in Andhra Pradesh! 

Glenmark Pharmaceuticals Share Price Performance  

As of August 20, 2026, 1:08 pm, Glenmark Pharmaceuticals share price was trading at ₹2,314.30, a 3.02% increase from the previous closing price. 

Conclusion 

Glenmark can market its Fluticasone Propionate Nasal Spray in the U.S. following FDA approval. The 0.05 mg-per-spray product will be distributed by Glenmark Pharmaceuticals Inc., USA. IQVIA data showed sales of about $295.2 million for the reference market in the year ended June 2026. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.   
 
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.